Market Newsdesk

FARMINGTON HILLS, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of two seminal papers supporting its APX3330 program. The first is a review paper on the Ref-1 protein, a novel molecular target involved in multiple inflammatory and angiogenic disease processes, focusing on ocular, gastrointestinal, and cancer disorders in Drug Discovery Today, a journal dedicated to all aspects of preclinical drug discovery. The second publication covers a preclinical study outlining the benefits of APX3330 that were shown in mouse models of chronic colitis, an inflammatory condition, in the peer-reviewed journal Inflammatory Bowel Disease.

The publication entitled, “The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease,” reported the following:

• Ref-1 has emerged as a novel therapeutic target developed for treating ocular diseases
• Findings in other indications, such as in preclinical models of cancer and IBD, support the targeting of Ref-1 to interfere with angiogenesis and inflammation in ocular disease such as diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD) with APX3330, APX2009, and APX2014
• Findings from a solid tumor Phase-1 trial, where doses up to 600 mg per day of APX3330 demonstrated chronic tolerability, for some patients up to a year
• Use of Ref-1 inhibitors has also promoted prevention of neuropathy in preclinical studies

The full online publication can be accessed at the following link: sciencedirect.com

The second publication entitled, “Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis,” reported the following:

• Inflammation-induced oxidative stress is implicated in the pathophysiology of GI dysfunction in IBD

• When given systemically to mice with chronic colitis, APX3330 reduced mitochondrial superoxide production, oxidative DNA damage, leading to neuroprotective effects of the enteric nervous system
• APX3330 improved disease severity, reduced immune cell infiltration, restored GI function, and demonstrated Ref-1 target inhibition

The full online publication can be accessed at the following link: academic.oup.com

Mark Kelley, PhD, member of Ocuphire’s Ocular Medical Advisory Board, commented, “The results presented in both publications support the underlying mechanism of action of Ref-1 inhibitors in the prevention of inflammation and angiogenesis as well as the potential chronic daily use of APX3330 for ocular diseases.”

These publications offer evidence on the anti-inflammatory and anti-angiogenesis benefits of APX3330, and with the increasing implications of inflammatory pathways in diabetic eye disease, there is significant promise for its success in treating diabetic retinopathy, macular edema, and wet age-related macular degeneration.

APX
3330 to be Investigated in the
ZETA-1 Phase 2 Trial in Diabetic Retinopathy

The planned multi-center, randomized, placebo-controlled, double-masked Phase 2 study is designed to evaluate the efficacy of daily oral dosing of APX3330 to improve Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR). The trial is expected to enroll 100 patients in early 2021 over multiple sites in the US and will evaluate a 600mg daily dosage of APX3330 over the course of 24 weeks. The primary endpoint will be the percentage of patients with a ≥ 2-step improvement in DRSS score in the study eye at week 24. Please refer to ocuphire.com for more information.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol^® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s recent Phase 2 clinical trials. For more information, please visit www.ocuphire.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates and potential. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (i
ii
) changes to clinical trial designs and regulatory pathways; (
i
v) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, and (vii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC (including the proxy statement/prospectus included in that certain Registration Statement on Form S-4 (File No. 333-239702) initially filed with the SEC on July 6, 2020 and declared effective by the SEC on October 2, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Ocuphire Contact:

Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
(248) 681-9815
[email protected]
www.ocuphire.com

Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –

–  Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency –

–  Expect to initiate INZ-701 Phase 1/2 clinical trials for ENPP1 and ABCC6 deficiencies in first half of 2021 –

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

“ENPP1 deficiency is a systemic, progressive and continuous disease occurring over the course of a patient’s lifetime, starting as early as fetal development and spanning into adulthood. The fact that INZ-701 had previously received orphan drug designation and now rare pediatric disease and fast track designations underscores the significant unmet medical need for a treatment for this disease,” said Axel Bolte, MSc, MBA, co-founder, president and chief executive officer of Inozyme Pharma. “I’m pleased with the progress we have made with U.S. and European regulatory authorities, and we remain on track to initiate our planned Phase 1/2 clinical trials in the first half of 2021, subject to clearance of our regulatory applications.”

Recent Business Highlights

• Submitted Clinical Trial Application (CTA) for INZ-701 for the treatment of ENPP1 deficiency – Inozyme recently submitted its first CTA to initiate a Phase 1/2 clinical trial of INZ-701 for the treatment of ENPP1 deficiency to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
• Received Rare Pediatric Disease Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for INZ-701 for the treatment of ENPP1 deficiency – The FDA grants rare pediatric disease designation to drugs for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect children aged from birth through 18 years and affect fewer than 200,000 people in the U.S. Under the FDA’s Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives approval of a biologics license application (BLA) for a rare pediatric disease product application may be eligible for a voucher which can be redeemed to obtain priority review for a subsequent marketing application for a different product. Separately, Fast Track Designation facilitates the potential expedited development and review of a drug for the treatment of a serious or life-threatening disease and that has demonstrated the potential to address unmet medical needs. Benefits of this designation include frequent engagements with the FDA to discuss the drug’s clinical development plan, eligibility for priority review, and a rolling review of a BLA. Previously, the FDA and the European Medicines Agency (EMA) had granted orphan drug designation to INZ-701 for the treatment of ENPP1 deficiency.
• Completed disease burden study in ENPP1 deficiency and ABCC6 deficiency – Inozyme and GACI Global, a patient advocacy organization dedicated to bettering the lives of families affected by Generalized Arterial Calcification of Infancy and/or Autosomal Recessive Hypophosphatemic Rickets Type 2 (GACI/ARHR2), completed a study to characterize the burden of disease and understand the systemic progression of disease for the rare genetic diseases of both ENPP1 deficiency and ABCC6 deficiency from the perspective of a patient and/or parent. Inozyme expects to share data from this study in 2021.

Upcoming Anticipated Milestones, Subject to COVID-19 Dynamics

• INZ-701 for ENPP1 deficiency
  • Early 2021: Clearance of IND and CTAs
  • H1 2021: Initiation of Phase 1/2 clinical trial
  • H1 2021: Initiation of prospective natural history study
  • H2 2021: Preliminary safety and biomarker data from Phase 1/2 clinical trial
•  INZ-701 for ABCC6 deficiency
  • Early 2021: Clearance of CTAs
  • H1 2021: Initiation of Phase 1/2 clinical trial
  • H2 2021: Preliminary safety and biomarker data from Phase 1/2 clinical trial

Upcoming Investor Conference

• Piper Sandler 32nd Annual Healthcare Conference, November 30 – December 3, 2020

Third Quarter 2020 Financial Results

• Cash Position and Financial Guidance – Cash, cash equivalents and investments were $171.7 million as of September 30, 2020. Based on its current plans, the Company expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements at least into the second half of 2022.
• Research and Development (R&D) Expenses– R&D expenses were $25.2 million for the third quarter ended September 30, 2020, compared to $3.3 million for the same period in 2019. The increase was primarily due to an increase of $17.8 million resulting from the non-recurring, non-cash purchase of in-process research and development intellectual property assets from Alexion in exchange for stock of the Company in July 2020, costs associated with preclinical studies and clinical preparation activities with the Company’s CRO, and growth in the number of R&D employees.
• General and Administrative (G&A) Expenses – G&A expenses were $3.1 million for the third quarter ended September 30, 2020, compared to $1.0 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees, an increase in legal fees related to patents, new contracts and operations as a public company, and generally higher fees in areas such as audit, tax and information technology to support the Company’s growth.
• Net Loss – Net loss was $28.1 million, or $1.55 loss per share, for the third quarter ended September 30, 2020, compared to $4.0 million, or $3.38 loss per share, for the same period in 2019.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY), is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our future clinical trials, our research and development programs, the availability of preclinical study and clinical trial data, the timing of our regulatory applications and the period over which we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to successfully resolve the clinical hold with regard to its planned Phase 1/2 clinical trial of INZ-701 for ENPP1 deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Condensed Consolidated Balance Sheet Data
(Unaudited)

(in thousands)

	September 30, 2020				December 31, 2019
Cash, cash equivalents and investments	$	171,709			$	47,132
Total assets		178,993				47,944
Total liabilities		11,077				3,236
Convertible preferred stock		—				77,927
Additional paid-in-capital		247,872				1,428
Accumulated deficit		(79,958	)			(34,652	)
Total stockholders’ equity (deficit)		167,916				(33,219	)

Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)

(in thousands, except share and per share data)

	Three Months Ended September 30,								Nine Months Ended September 30,
	2020				2019				2020				2019
Operating expenses:
Research and development	$	25,174			$	3,317			$	39,457			$	10,941
General and administrative		3,142				1,003				6,313				3,097
Total operating expenses		28,316				4,320				45,770				14,038
Loss from operations		(28,316	)			(4,320	)			(45,770	)			(14,038	)
Other income (expense):
Interest income		64				288				306				892
Other income (expense), net		157				(3	)			158				(34	)
Other income (expense), net		221				285				464				858
Net loss	$	(28,095	)		$	(4,035	)		$	(45,306	)		$	(13,180	)
Other comprehensive (loss) income:
Unrealized (losses) gains on available-for-sale securities		(13	)			(2	)			(5	)			8
Total other comprehensive (loss) income		(13	)			(2	)			(5	)			8
Comprehensive loss	$	(28,108	)		$	(4,037	)		$	(45,311	)		$	(13,172	)
Net loss attributable to common stockholders—basic and diluted	$	(28,095	)		$	(4,035	)		$	(45,306	)		$	(13,180	)
Net loss per share attributable to common stockholders—basic and diluted	$	(1.55	)		$	(3.38	)		$	(6.57	)		$	(11.20	)
Weighted-average common shares outstanding—basic and diluted		18,101,496				1,195,309				6,893,745				1,176,769

Investors:
Brian Luque, Director, Investor Relations
(951) 206-1200
[email protected]

Media:

Alex Van Rees, SmithSolve
(973) 442-1555 ext. 111
[email protected]

SAN JOSE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — OpsRamp, a modern SaaS platform for hybrid infrastructure discovery, monitoring, management, and automation, today announced the launch of a new report: “The Change Agents: How IT Operations Teams Are Driving Enterprise Transformation and Value Creation During Uncertain Times.”

In April 2020, OpsRamp published its Thriving in the New Normal: How IT Operations Leaders Can Deliver Business Value in an Economic Slowdown report to analyze how IT teams were adapting technology priorities, staff hiring, and spending plans in response to the pandemic. As the global health crisis continues, OpsRamp conducted a follow-up survey in October 2020. The new survey is based on responses from 230 IT operations and DevOps executives in the U.S. and U.K. with at least 500 employees and $5 million in annual IT budgets. The survey asked about annual spending plans, cost reduction measures, operational challenges, and investment themes for 2020 and beyond.

Here are the top three insights from the report:

IT is a Strategic Differentiator: In the face of restrictive lockdowns and stay-at-home orders, IT budgets have held up remarkably well as technology becomes a critical ingredient in launching new products and services.

• In the second and third quarters of 2020, 60% of IT leaders significantly or moderately increased their annual technology budgets while only 22% significantly or moderately reduced their IT spending in the last two quarters.
• Meanwhile, 63% of participants reported that Covid-19 led them to accelerate or maintain digital transformation initiatives.

Business Priorities Dictate IT Investments: The leading technology investments in the April 2020 survey were information security and compliance, big data and analytics, and public and multi-cloud infrastructure. These priorities have broadly remained the same in the October survey, but remote work and collaboration have grown in importance.

• What is front and center for IT budgets? The critical priorities for IT leaders include information security and compliance (59%), remote work and collaboration (55%), public and multi-cloud infrastructure (50%), and monitoring and management (42%). The pandemic has made digital touchpoints a critical differentiator for customer interactions while resilient technology infrastructure remains a priority for employees working remotely.
• What performance monitoring tools did IT teams buy in 2020? In 2020, technology leaders focused on the following tools to ensure compelling customer and employee experiences.
  — Artificial intelligence for IT operations (57%) solutions help technology practitioners maintain the uptime, reliability, and performance of technology services with contextual, actionable, and predictive insights.
  — Digital experience monitoring (50%) tools put a clear spotlight on business transactions and customer journeys by surfacing end-user interaction insights for complex enterprise services.
  — Network performance monitoring and diagnostics (50%) tools ensure responsive network infrastructure with instrumentation analytics and visualizations for device, flow, and packet-level data.

IT Cost Management and Hiring During Covid-19: With global IT spending expected to fall by 7.3% in 2020, technology leaders have had to employ creative measures to get the most bang for their bucks. IT teams are looking to hire people who can not only help them stay relevant during the pandemic but also build a proper foundation for growth when the economy eventually recovers in 2021.

• Cost reduction measures. Technology leaders have used self-service tools (60% in October versus 54% in April), embraced open source (51% in October versus 50% in April), and reduced technology suppliers (51% in Octobers versus 59% in April) to save money and rationalize their IT operations portfolios.
• Hiring priorities. Enterprises have either recently hired or are planning to recruit the following team members:
  — Financial managers (54%) who can help IT teams present a compelling business case for technology investments,
  — Senior IT leaders (47%) who can marshal the right resources to successfully execute digital transformation programs, and
  — Cloud operators (44%) who can shift, monitor, and maintain enterprise workloads on public cloud infrastructure.

“I’m not surprised that the majority of companies are pressing ahead with digital transformation projects and increasing spend despite the pandemic,” said Varma Kunaparaju, CEO of OpsRamp. “Organizations that fail to make sound IT investments in this critical phase will lose customer mindshare, fall behind their competition, and slowly become irrelevant in a global economy that is delivering disproportionate returns for digital leaders. What does stand out is the number of companies hiring financial managers to help IT teams justify new technology. Reckless spending on the latest shiny tech toy is being replaced by thoughtful, data-driven decision making, which bodes well for the entire industry.”

The report is available for download here.

About OpsRamp

OpsRamp
is an IT operations management software company whose SaaS platform is used by enterprise IT teams to monitor and manage their cloud and on-premises infrastructure. Key capabilities of the OpsRamp platform include: hybrid infrastructure discovery and monitoring, event and incident management, and remediation and automation, all of which are powered by artificial intelligence. OpsRamp investors include Sapphire Ventures, Morgan Stanley Expansion Capital and HPE.

Visit the OpsRamp Newsroom for all media coverage and press releases.

Visit the OpsRamp Blog.

OpsRamp on Twitter: https://twitter.com/OpsRamp

OpsRamp on LinkedIn: https://www.linkedin.com/company/opsramp

Media contact:

Kevin Wolf

TGPR

(650) 483-1552

[email protected]

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99349270-dae8-4953-b4ba-5c39a7c830c5

https://www.globenewswire.com/NewsRoom/AttachmentNg/21059407-fa46-47c8-a946-31d815e58dbd

Allows for Increases in Private Label and Direct-to-Consumer

HICKSVILLE, NY, Nov. 12, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a diversified health and wellness company, is pleased to announce the installation of new high-speed equipment to expand production at its Pure Health Products (“PHP”) facility in Lacey, Washington.

The new production line equipment increases capacity by 8,000 units per day and adds speed and efficiency with automated processes. Upgrading from manual to automated equipment for tinctures, salves, cryogels, and massage oils greatly increase the production output by over three hundred percent (300%). The increase in capacity enables the Company to expand its capabilities in private label and direct-to-consumer.

Marco Alfonsi, Can B’s Chief Executive Officer, commented, “We are pleased to announce that phase two of upgrading the manufacturing capacity is nearly complete. The final equipment has been fully tested and installed in our Lacey, Washington facility’s production cleanroom. This upgrade allows Pure Health Products to produce up to 10,000 units a day of bottles, tinctures, salves, lotions, or creams combined. The plant capacity will allow a potential bottling production of $40 million in sales at wholesale price.”

Shanghai Panda Intelligent Machinery Co. was charged with the task of building a custom bottling line, designed by David Posel, Chief Scientist of PHP. The bottling line features two independent main bottling machines that merge into a single shrink-film machine and heat-shrink tunnel. The machines and layout were designed specifically with the needs of producing the CBD industry’s core retail products in mind. This custom triple bottling line with unified shrink tunnel will fill, cap, label, and shrink band all products including droppers, sprays, salves, lotions, creams, capsules, and cryogels. The main tincture and spray bottling line and the bottling line that fills the larger lotions, salves, and creams are now fully operational and on-line.

The new Capsule Pouch Packing Machine was custom configured and manufactured by Ming Yue Packaging Machinery Co. to allow PHP to produce single-use packs of their popular capsule recipes, and custom or white-label products from 1 capsule to 12 capsules in each 3×3 inch retail pouch. This machine features a custom configured dual capsule feeding system, which allows two independently controlled precision capsule feeders to deposit into the same retail pouch. This uniquely allows PHP to produce any configuration of two different capsule blends in the same unit with up to 12 total capsules.

This concept gives PHP the leading edge in first-to-market packaging as no competitor has utilized this method to-date. The lot and expiration numbers are heat-stamped onto the edge of each packet to ensure proper consumer quality standards. This custom dual-feed packaging machine is rated to produce up to 10,000 packets per day.

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a Health & Wellness company providing the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B is also an exclusive partner of the LifeGuard® Brand in developing a line of consumer products. The Company is also launching Super Foods, a line of nutritional supplements. Can B Corp. owns and operates an R&D and production facility in Lacey, WA, and Green Grow Farms, a licensed hemp grow and cultivation in New York. To learn more about Can B Corp. and our comprehensive line of high-quality CBD products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape, or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Investors and Media:

[email protected]

(917) 658-7878

Seoul, South Korea, Nov. 12, 2020 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, today announced that Ragnarok X: Next Generation has been ranked as the first in top grossing of Google Play in Taiwan and Hong Kong followed by Apple App Store.  

As the No.1 title in top grossing of Google Play hasn’t changed easily, it shows the popularity of the game in Taiwan and Hong Kong has been growing rapidly.

Gravity said, ” In return for this heated local users’ support, we are doing our best with ByteDance Ltd., our publisher of Ragnarok X: Next Generation. We will try to make this game to be loved for a long term through interactive communications with more users.

ByteDance Ltd., a global IT company, publishes this game and Gravity Communications Co., Ltd., Gravity’s subsidiary in Taiwan, supports the ByteDance as a joint publisher.

[Ragnarok X: Next Generation Official Website] https://rox.gnjoy.com.tw/

 [Ragnarok X: Next Generation _Facebook Page] https://www.facebook.com/ROXNextGeneration

About GRAVITY Co., Ltd. —————————————————

Gravity is a developer and publisher of online and mobile games. Gravity’s principal product, Ragnarok Online, is a popular online game in many markets, including Japan and Taiwan, and is currently commercially offered in 93 markets and countries. For more information about Gravity, please visit http://www.gravity.co.kr.

Contact:

Mr. Heung Gon Kim
Chief Financial Officer
Gravity Co., Ltd.
Email: [email protected]

Ms. Jin Lee
Ms. Hye Ji An
IR Unit
Gravity Co., Ltd.
Email: [email protected]
Telephone: +82-2-2132-7800~1

– Investment
demonstrates DENSO’s commitment to corporate venture strategy, even in
challenging
times,
and supports company’s
push into new mobility areas
–

SOUTHFIELD, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — DENSO, a leading mobility supplier, today announced it has invested in Lambda:4, a German company that develops wireless positioning technologies for short-range applications using Bluetooth Low Energy. The investment will strengthen DENSO’s passive digital key, increasing its location accuracy and user authentication capabilities. This improves safety and security for those using the key on smart devices to enter a vehicle.

Passive digital keys allow approved users to connect their smart devices, such as smart phones, to vehicles without the user ever having to touch a button or open an app. Through the passive digital key, a car can identify when an approved user is approaching; when the approved user is at the car door, unlocking it; and when the approved user is inside, enabling ignition. For this sequence to progress seamlessly, it is critical for the vehicle to be able to quickly identify and authenticate an approved user and pinpoint their location in and around the car.

Lambda:4’s expertise, perfected in producing localization systems for avalanche search and rescue missions, will rapidly increase DENSO’s innovation in localization systems.

“As much of society goes digital, we are building a connected ecosystem that bridges the gap between consumer and automotive technologies,” said Ron Schubert, director of Body Electronics Systems at DENSO. “We believe that personalized passive access to vehicles, owned by individuals or deployed in shared fleets, will help make road travel more convenient, secure and enjoyable for commuters.”

The investment is the latest development in DENSO’s work with passive digital keys, which goes back to 2012, when it began developing the technology. Since then, DENSO has become a leader in the space, continually advancing the micro-locating performance of its solution. In 2017, the company acquired InfiniteKey, further expanding the key’s functionality. DENSO’s integrated key is now on the road today.

“Our goal at DENSO is to create products and technologies that enhance mobility and meet our partners’ needs, helping them deliver seamless and user-friendly experiences to their customers,” said Tony Cannestra, director of Corporate Ventures at DENSO. “We are pleased to forge ahead with this investment not only despite the coronavirus pandemic, but because it will help us develop safer transportation solutions during it. We continue to focus on new mobility areas and potential partners, particularly in connectivity and autonomy, who can help us address transportation needs of today and beyond.”

A pioneer in phase-based ranging technology, Lambda:4 has accrued more than 15 years of experience and patents in ranging and positioning technologies used in complex multi-pathing environments. Now, as a leader in core positioning system technology and intellectual property, the company is poised to capitalize on the expanding need for location-aware solutions.

“Digitizing the world is an ongoing trend. By using standard Bluetooth chipsets, our technology offers a low-cost, universal way to enable location aware applications, like passive access and digital keys,” said Rönne Reimann, CEO of Lambda:4. “We are thrilled to have DENSO at our side to share the same vision about a world with seamless access – be it your car, a hotel or your home.” 

As part of the company’s Second Founding, DENSO is committed to boosting its research and development efforts by expanding into new mobility areas where it sees opportunities to make transportation more efficient, safer and sustainable for all.

About DENSO

DENSO is a $47.6 billion global mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in its 200 facilities to produce thermal, powertrain, mobility, electrification, & electronic systems, to create jobs that directly change how the world moves. The company’s 170,000+ employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. Globally headquartered in Kariya, Japan, DENSO spent 9.9 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2020. For more information about global DENSO, visit https://www.denso.com/global.

In North America, DENSO is headquartered in Southfield, Michigan, and employs 27,000+ engineers, researchers and skilled workers across 51 sites in the U.S, Canada and Mexico. In the United States alone, DENSO employs 17,700+ employees across 14 states (and the District of Columbia) and 41 sites. In fiscal year ending March 31, 2020, DENSO in North America generated $10.9 billion in consolidated sales. DENSO is committed to advancing diversity and inclusion inside the company and beyond – a principle that brings unique perspectives together, bolsters innovation and pushes DENSO forward. Join us, and craft not only how the world moves, but also your career: densocareers.com. For more information, go to https://www.denso.com/us-ca/en/.

About Lambda
:4

Lambda:4 was founded in Hamburg, Germany. With a team of 13 employees including veterans from the automotive and wireless connectivity industry, Lambda:4 is focused on providing the most accurate, robust and secure wireless ranging technology. Over the last years Lambda:4 developed many patents and prototypes concentrating on keyless entry systems. Lambda:4 develops low level routines to optimize chipsets for use with their technology and embedded high level algorithms to calculate the range or a position. For more information, go to http://www.lambda4.com/en/

Contact:
Andrew Rickerman

DENSO International America, Inc.
(734) 560-8752
[email protected]

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick and mortar space is pleased to announce the January 2021 launch of UKLIPZ, the first ever platform that enables consumers to create verified reviews using mobile video that can also be used, purchased or analyzed by brands and retailers to drive further engagement and sales. UKLIPZ was acquired by Loop on September 16th, 2019.

Loop Insights CEO, Rob Anson, stated, “The long-awaited integration of UKLIPZ into our product stack is a very important milestone for Loop due to the significant strength it adds to our offering and the disruption it creates in the massive but problematic consumer review industry. We have already begun discussions with key brands and retailers and believe UKLIPZ will become both a very significant new stream of revenue and valuable asset in 2021.”

THE PROBLEM – AMAZON AND WALMART FLOODED WITH FAKE REVIEWS DURING PANDEMIC

On October 19th, Bloomberg News reported that approximately 42% of 720 million Amazon reviews assessed by monitoring service Fakespot were unreliable, while approximately 36% of Walmart.com reviews assessed by Fakespot during the same period were fake.

THE SOLUTION – LOOP ACCESS TO TRANSACTIONS AUTHENTICATES CONSUMER REVIEWS

Customer reviews have become the cornerstone of every retail and e-commerce platform because 63% of customers are more likely to purchase from a site with user reviews. In 2019, YELP, the business review site, generated over $USD 1.01 Billion in revenue.

Loop has the ability to access 100% of all transactions both in-store and online, where our technology is deployed through either our IoT device Fobi (i.e., TELUS IoT marketplace customers) or our POS integration partners such as Vend, Shopify, and others.

As a result of this transparency, Loop can validate the authenticity of consumer reviews posted on the UKLIPZ platform. This unique ability provides a strong differentiator regarding any other deemed competitive platforms in the marketplace today.

UKLIPZ is set to disrupt the social, video marketing, and review industry, which is expected to reach $52B USD by 2023, according to Statista.

THE ADVANTAGES FOR BRANDS AND CONSUMERS

For brands, UKLIPZ will simplify the process of sourcing, creating, curating, and licensing authentic customer reviews. Furthermore, UKLIPZ offers brands real-time measurable attribution for hyper-local, regional, and national campaign performance metrics. Moreover, it can provide brands with digital focus groups and product testing campaigns, as well as target and seek out reviews from specific audiences based on demographics and interests.

Current review sites and solutions simply cannot provide this level of detail and engagement.

For consumers, UKLIPZ provides them with an ability to create a verified and direct connection with their favourite brands, which opens the door to generating income from creating further video reviews, participating in product testing, and other opportunities.

For consumers, curated content created by them is arguably the most powerful influencer of brand and product sales today. The UKLIPZ platform enables consumers to create authenticated video reviews, create a verified and direct connections with their favourite brands, and potentially turn them into income-generating brand influencers and ambassadors.

MONETIZATION AND FURTHER STRENGTHENING THE LOOP INSIGHTS OFFERING

The launch of the UKLIPZ platform is another important strategic move by providing our partners and customers with another immediate complimentary plug-in to expand and significantly strengthen the current Loop solution offering.

Revenues from UKLIPZ will be generated through multiple streams as follows:

• Monthly SaaS fees from Brands and Retailers;
• Transaction fees when a consumer purchases through the platform
• Brands purchasing use of consumer video reviews;
• Sponsored ads

User-generated content drives a 74% increase in click-through rates, while 45% of marketers surveyed by Forrester agree that user-generated content improves social media advertising and influencer campaigns. UKLIPZ provides brands with an easy way to incentivize and empower customers, employees, and influencers to engage and promote the products they love. This is especially true given that word-of-mouth advertising remains the richest path to authenticity, new customers, and ROI.

As a result of the Covid -19 pandemic, the global retail market faces its largest challenge in decades. According to Forrester.com, the latest forecast on global retail sales deficit will mass more than $2.1 Trillion in 2020. The strong shining light is the emergence and rise in mobile commerce. With an expected increase of 25.6%, Mobile is the growth engine of digital commerce. As a result of Covid-19, consumers have been forced to educate themselves and to embrace mobile and e-commerce, and rely on online retailers for their purchase. As a result of the rapid digital transformation, consumer authentic and trusted reviews have never been more important to consumers, brands, and retailers. The company is confident that it will greatly benefit from strong revenue growth from the built-in mobile commerce within UKLIPZ.

AMAZON PARTNER DESIGNATION OPENS UP DOORS TO GLOBAL FORTUNE 500 RETAILERS AND BRANDS 

Rob Anson added, “Every brand on the planet is looking for two things, direct access to their consumer and to understand their behaviour across all channels including e-commerce, mobile commerce, and in-store commerce. UKLIPZ will deliver the sought-after data intelligence through our Artificial Intelligence platform and facilitate direct brand to consumer access and connection.” 

This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/LoopInsights

Watch more here:



https://vimeo.com/359399719

About Uklipz

Loop’s vision for Uklipz is to build a global brand as the premier, trusted source of authentic, user-generated reviews using technology that allows anyone with a smartphone to create, post, and monetize video reviews. Uklipz revolutionizes digital brand and marketing assets by offering a direct and highly personalized feedback loop. With Uklipz, customers are literally at your fingertips. Brands gain an ability to engage directly with consumers in the heat of the moment, both in-store and online.

About Loop Insights
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.

For more information, please contact:
Loop Insights Inc.		LOOP Website: www.loopinsights.ai
Rob Anson, CEO		Facebook: @LoopInsights
T: +1 877-754-5336 Ext. 4		Twitter: @LoopInsights
E: [email protected]		LinkedIn: @LoopInsights

Forward-Looking Statements/Information:
 

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SAN JOSE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Secure, reliable transfer of data from IoT devices to a cloud environment is an escalating problem as businesses continue to scale complex IoT solutions. To provide a simple, economical and effective solution, Aeris, an IoT technology leader, today introduced Aeris Cloud Connect, which provides a direct, private connection between the Aeris Fusion IoT Network and each customer’s AWS cloud instance.

Cloud Connect uses an underlying MPLS (multi-protocol label switching) connection to enable data from IoT devices to be transferred directly to the cloud, without the need for a VPN and without sending data over the public internet. 

“Our customers worldwide have been seeking a means of better securing their data transfer from connected devices to the cloud,” said Amit Khetawat, Aeris vice president of products. “We know VPNs are costly and still vulnerable to internet traffic jams, and the public internet cannot provide the level of security businesses need. Our answer is Cloud Connect. It is secure, reliable and can be set up in hours,” he noted.

Key Cloud Connect benefits include:

• Superior reliability and security. Cloud Connect offers better uptime compared to VPNs. It also eliminates exposure to the public internet (a point of vulnerability) without introducing another potential point of failure (VPN) into the solution, improving end-to-end reliability and reducing troubleshooting time. 
• Faster time to market. Aeris Cloud Connect can be easily configured through a few drop-down menus in AWS in hours, accelerating time to market. By comparison, VPNs take 4-7 days to acquire and manually configure.
• Lower latency and high performance.  Cloud Connect’s private infrastructure provides a faster and far more stable connection than the public internet, which is always subject to congestion.
• Cost savings. Cloud Connect provides all of these benefits for less than the cost of comparable services, including VPN.

“Deploying and managing IoT solutions can be complex, requiring businesses to integrate and operationalize components from hardware, wireless connectivity, cloud environment, and potentially many other software stacks,” said Khetawat. “Aeris Cloud Connect is an important step toward bridging the often siloed network and cloud environments, providing material improvements in end-to-end IoT solution performance, scalability and cost efficiency.”

Cloud Connect is available now. To learn more visit: www.aeris.com

About Aeris

Aeris is a global technology partner with a proven history of helping companies unlock the value of IoT. For more than a decade, we have powered critical projects for some of the most demanding customers of IoT services. Aeris strives to fundamentally improve businesses by dramatically reducing costs, accelerating time-to-market, and enabling new revenue streams. Built from the ground up for IoT and road tested at scale, Aeris’ offering is based on the broadest technology stack in the industry, spanning connectivity up to vertical solutions. As veterans of the industry, we know that implementing an IoT solution can be complex, and we pride ourselves on making it simpler.

Contact:

Jennifer Spoerri                                                                 
Gallagher PR
+1 415-577-0171
[email protected]

ZIONSVILLE, Ind., Nov. 12, 2020 (GLOBE NEWSWIRE) — 120Water, a digital water platform in use at more than 180,000 sample sites across the nation, has joined forces with PUR Community, a new municipality initiative created by PUR, a Helen of Troy brand specializing in at-home water filtration, to simplify point of use drinking water programs for utilities, municipalities, and facilities, including lead remediation programs. Click to tweet.

With this partnership, 120Water can offer PUR pitcher and filter kits as part of its comprehensive digital water platform used across the country to manage and modernize complex water programs and to help stay compliant with EPA regulations, including the upcoming revised Lead & Copper Rule (LCR).

120Water helps water professionals maintain compliance with an end-to-end solution that automates the sending and tracking of tap water test kits; unifies all related data, including customer information, service lines, and water quality results; manages the fulfillment of filter/pitcher kits to affected consumers; and provides out-of-the-box communications, reports, and dashboards, including a Public Transparency Dashboard of known lead service lines.

120Water is a natural fit with the recently launched PUR Community initiative, which is designed as a resource to educate municipalities experiencing water quality issues and help with immediate and cost-effective point-of-use filtration solutions to help reduce lead. PUR Community extends on the PUR brand’s experience supporting communities that have been impacted by elevated levels of lead in the water. In the past seven years, PUR has distributed more than half a million point-of-use water filtration systems and replacement filters to help residents in affected cities through municipal partnerships.

“We created PUR Community because we know that collaboration is a critical part of the solution to improve access to safer drinking water across the country. We’re thrilled to work with an industry leader like 120Water as this will further our ability to provide pitcher and filters to communities as a short-term solution as they tackle long-term change, most notably lead remediation,” said Mike Mitchell, Director of Advanced Technologies of the Health and Home division, at Helen of Troy.

“Water providers are under a lot of pressure to deliver a safe and affordable supply of drinking water, and EPA revisions to the Safe Drinking Water Act will tax them even further,” said Megan Glover, CEO of 120Water. “120Water is excited to be working with PUR as we continue to build relationships with the best water quality companies to deliver trusted, end-to-end solutions for drinking water compliance, and to foster reliable remediation programs.”

120Water’s turnkey platform was built specifically for the water industry to manage a broad scope of drinking water programs, such as lead service line replacement, and can be applied to multiple contaminants, including lead and arsenic.

About 120Water

Water professionals across the country rely on 120Water to streamline and modernize their most complex drinking and waste water initiatives. The 120Water platform consists of sample & filter kits, cloud-based software, and services used to manage and execute water programs at scale while saving operational resources. 120Water solutions are used in 180,000 locations across the United States for clients including the city of Newark (NJ), Pittsburgh Water and Sewer Authority, Chicago Public Schools, and Indiana Finance Authority. More information is available at 120Water.com and on Twitter @120_Water.

About PUR Community

PUR Community was developed by Helen of Troy as a resource for local cleaner water efforts, which provides pitcher and faucet filtration products as short-term solutions for communities tackling long-term change. PUR Community is a partnership that combines PUR’s industry leading technology and expertise with the municipality’s unique insights, gained from serving their communities every day, to create a customized program.

PUR is a pioneer in water filtration technology and is committed to continued innovation and rigorous testing to provide safer water solutions for communities. Made up of chemical and mechanical engineers with over 40 years of combined experience and expertise in advanced filtration technologies, water quality testing, and manufacturing best practices, PUR is consistently engaged with the larger water community through organizational relationships with the WQA, AWWA, NSF and EPA. In the past seven years, PUR has distributed more than half a million filters to help residents in affected cities across the country through municipality partnerships and donations.

About PUR:

Owned by Helen of Troy Limited (NASDAQ: HELE), PUR® is a leading brand in the at-home water filtration category for faucet water filters, water pitchers and dispensers, and replacement filters. PUR is committed to superior filtration performance and innovation. PUR filtration technology uses activated carbon and ion exchange to reduce more contaminants than any other brand. Certified by NSF International and the Water Quality Association for their contamination reduction, PUR filtration systems were the first to claim reduction of trace levels of pharmaceuticals identified in U.S. tap water. PUR faucet filters are certified to reduce over 70 contaminants including lead, mercury and certain pesticides, while PUR pitcher and dispenser filtration systems are certified to reduce many contaminants including mercury and certain industrial pollutants. For more information about PUR water filtration visit PUR.com.

For information contact:

Linda Muskin, 847-432-7300
[email protected]

Mara Conklin, 847-816-9411
[email protected]

Taylor Jeffrey, 401 749 8810
[email protected]

SAN FRANCISCO and BERLIN and TEL AVIV, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) — AllCloud, a leading global cloud services provider and Amazon Web Services (AWS) Premier Consulting Partner, has been named the APN Social Impact Partner of the Year in the DACH region (Austria, Germany and Switzerland) and the APN Migration Partner of the Year in Israel. The APN Partner Awards recognize members of the AWS Partner Network (APN) who are leaders in the channel and play a key role in helping customers to drive innovation and build solutions on AWS.

AllCloud was recently named one of America’s fastest growing private companies, with three-year revenue growth of 330%. Though the company has its global headquarters in the U.S., it was founded in Israel and supports numerous clients in the country. Within the last few years, AllCloud expanded its operations in Europe. The company has offices across Germany, with a delivery center in Bucharest, and dozens of clients throughout the DACH region.

An Audited AWS Managed Service Provider (MSP) Program Partner that has achieved six AWS Competency designations, AllCloud accelerates cloud innovation and helps organizations unlock the value of AWS services. Supported by a robust ecosystem of technology partners, proven methodologies and well-documented best practices, AllCloud elevates its clients by helping them achieve operational excellence in the cloud, at every milestone of their journey.

AllCloud earned the APN Social Impact Partner of the Year award in DACH for its work with EyeControl, provider of an AI-powered wearable personal communication device for people whose medical condition prevents them from communicating effectively. AllCloud helped EyeControl improve the accuracy of its solution using AWS services. A demonstration can be viewed in the Digital Builders Showroom in the AWS Munich office.

AllCloud was chosen as the APN Migration Partner of the Year in Israel for becoming the first AWS Partner in the country to earn the AWS Migration Competency, which recognizes partners that have helped clients migrate applications and legacy infrastructure to AWS.

“We are incredibly honored to receive these awards,” said Eran Gil, CEO of AllCloud. “They speak to the hard work of our teams in Europe, Israel and around the globe, and their commitment to helping clients use AWS services to serve their customers and communities. We thank AWS for honoring us and look forward to continued success as an AWS Partner as we continue our expansive growth.”

About AllCloud

AllCloud is a global professional services company providing organizations with the tools for cloud enablement and transformation. Through a unique combination of expertise and agility, AllCloud accelerates cloud innovation and helps organizations fully unlock the value received from cloud technology.

As an Amazon Web Services (AWS) Premier Consulting Partner and a Salesforce Platinum Partner, AllCloud helps clients connect their front office and back office by building a new operating model that allows them to harness the benefits of both AWS and Salesforce. AllCloud is supported by a robust ecosystem of technology partners, proven methodologies, and well-documented best practices. Thereby, elevating customers by achieving operational excellence on the cloud, within a secure environment, at every milestone of the journey to becoming cloud-first.

With a portfolio of thousands of successful cloud deployments, AllCloud serves clients across the globe. AllCloud has offices in Israel, Europe, and North America.

Media contact:
Kevin Wolf
TGPR
(650) 483-1552
[email protected]